Corbus Pharmaceuticals (CRBP) Price & Analysis

Compare

2,420 Followers

CRBP Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.64 - $20.77

Previous CloseN/A

Volume39.58K

Average Volume (3M)139.01K

Market Cap

$159.44M

Enterprise Value-$29.96M

Total Cash (Recent Filing)$20.04M

Total Debt (Recent Filing)$2.46M

Price to Earnings (P/E)―

Beta2.10

Next Earnings

Nov 11, 2025

EPS Estimate

-1.71

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.44

Shares Outstanding12,255,225

10 Day Avg. Volume153,751

30 Day Avg. Volume139,008

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)0.90

Price to Sales (P/S)0.00

P/FCF Ratio-3.08

Enterprise Value/Market Cap-0.19

Enterprise Value/Revenue-42.60

Enterprise Value/Gross Profit54.88

Enterprise Value/Ebitda0.52

Forecast

1Y Price Target

$43.50

Price Target Upside193.32% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyPhase I data in heavily pretreated HNSCC showed a 57% objective response rate, indicating promising efficacy that now requires validation in larger Western cohorts.

Financial PositionCorbus ended the second quarter with $116.6 million in cash, expected to fund operations through the second quarter of 2027.

Regulatory MilestonesThe FDA granted Fast Track Designation to CRB-701 in Head and Neck Squamous Cell Carcinoma, marking the second Fast Track designation for this drug.

Bears Say

Financial PerformanceCorbus reported a net loss of $17.7 million, which was worse than the estimate of a loss of $11.0 million.

Short InterestShort interest in Corbus Pharmaceuticals is relatively high at 18.2% of the float.

Corbus Pharmaceuticals News

Why Are Cannabis Stocks Up Today?

Cannabis stocks rallied on Monday thanks to a video that was shares by President Donald Trump. ...

6d ago

CGC

SMG

Corbus Pharmaceuticals receives Fast Track designation for CRB-701

Corbus Pharmaceuticals (CRBP) announced that the U.S. Food and Drug Administration has granted Fast Track designation to CRB-701...

19d ago

CRBP

Corbus Pharmaceuticals’ CRB-701: A Promising Investment with FDA Fast Track and ESMO 2025 Insights

Corbus Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andres Y. Maldonado...

18d ago

CRBP

Corbus Pharmaceuticals Receives FDA Fast Track for CRB-701

An announcement from Corbus Pharmaceuticals ( ($CRBP) ) is now available. On September 16, 2025, Corbus Pharmaceuticals announced...

19d ago

CRBP

Corbus Pharmaceuticals: Promising Clinical Programs and Strong Financial Position Drive Buy Rating

Analyst Oliver McCammon of LifeSci Capital maintained a Buy rating on Corbus Pharmaceuticals, with a price target of...

2M ago

CRBP

Corbus Pharmaceuticals: Promising Pipeline and Strategic Advancements Justify Buy Rating

Analyst Andres Y. Maldonado from H.C. Wainwright reiterated a Buy rating on Corbus Pharmaceuticals and keeping the price...

2M ago

CRBP

Corbus Pharmaceuticals price target lowered to $53 from $56 at Oppenheimer

Oppenheimer lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $53 from $56 and keeps an Outperform...

2M ago

CRBP

Corbus Pharmaceuticals Reports Q2 2025 Financials and Updates

Corbus Pharmaceuticals Holdings ( ($CRBP) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

CRBP

Corbus Pharmaceuticals: Promising Outlook with Key Data Releases and Strong Financial Position

William Blair analyst Andy Hsieh has reiterated their bullish stance on CRBP stock, giving a Buy rating on...

2M ago

CRBP

Corbus Pharmaceuticals Receives FDA Fast Track Designation

An update from Corbus Pharmaceuticals ( ($CRBP) ) is now available. Corbus Pharmaceuticals reported its second quarter 2025...

2M ago

CRBP

Corbus Pharmaceuticals reports Q2 EPS ($1.44), consensus ($1.33)

“The second half of 2025 is shaping up to be impactful, with scheduled data readouts anticipated for all...

2M ago

CRBP

Corbus Pharmaceuticals transferred with Buy rating at B. Riley

B. Riley kept a Buy rating on Corbus Pharmaceuticals (CRBP) with a $28 price target following a transfer...

2M ago

CRBP

Corbus announces presentation of dose expansion Phase 1/2 data for CRB-701

Corbus Pharmaceuticals (CRBP) Holdings announced that an abstract on updated clinical data from its Phase 1/2 clinical study...

2M ago

CRBP

Corbus Pharmaceuticals initiates MAD portion of its Phase 1 trial for CRB-913

Corbus Pharmaceuticals (CRBP) announced the initiation of the multiple ascending dose, MAD, portion of its Phase 1 trial...

3M ago

CRBP

CRBP FAQ

What was Corbus Pharmaceuticals’s price range in the past 12 months?

Corbus Pharmaceuticals lowest stock price was $4.64 and its highest was $20.77 in the past 12 months.

What is Corbus Pharmaceuticals’s market cap?

Corbus Pharmaceuticals’s market cap is $159.44M.

When is Corbus Pharmaceuticals’s upcoming earnings report date?

Corbus Pharmaceuticals’s upcoming earnings report date is Nov 11, 2025 which is in 37 days.

How were Corbus Pharmaceuticals’s earnings last quarter?

Corbus Pharmaceuticals released its earnings results on Aug 05, 2025. The company reported -$1.44 earnings per share for the quarter, beating the consensus estimate of -$1.496 by $0.056.

Is Corbus Pharmaceuticals overvalued?

According to Wall Street analysts Corbus Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Corbus Pharmaceuticals pay dividends?

Corbus Pharmaceuticals does not currently pay dividends.

What is Corbus Pharmaceuticals’s EPS estimate?

Corbus Pharmaceuticals’s EPS estimate is -1.71.

How many shares outstanding does Corbus Pharmaceuticals have?

Corbus Pharmaceuticals has 12,255,225 shares outstanding.

What happened to Corbus Pharmaceuticals’s price movement after its last earnings report?

Corbus Pharmaceuticals reported an EPS of -$1.44 in its last earnings report, beating expectations of -$1.496. Following the earnings report the stock price went down -4.711%.

Which hedge fund is a major shareholder of Corbus Pharmaceuticals?

Currently, no hedge funds are holding shares in CRBP

Corbus Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-49.00%

Trailing 12-Months

Asset Growth

-17.70%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (CRBP) is a clinical-stage pharmaceutical company specializing in the development and commercialization of novel therapeutics for the treatment of inflammatory and fibrotic diseases. The company's primary focus is on harnessing the potential of the endocannabinoid system to develop drugs that address chronic diseases with significant unmet medical needs. Corbus is engaged in developing a pipeline of innovative drug candidates targeting these conditions, with a particular emphasis on rare inflammatory diseases.

Corbus Pharmaceuticals (CRBP) Earnings & Revenues

Historic Earnings Reports

CRBP Stock 12 Month Forecast

Average Price Target

$43.50

▲(193.32% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","33":"$33","62":"$62","18.5":"$18.5","47.5":"$47.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$43.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$28.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,18.5,33,47.5,62],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.74,13.221538461538461,16.70307692307692,20.184615384615384,23.666153846153847,27.14769230769231,30.629230769230766,34.11076923076923,37.59230769230769,41.073846153846155,44.55538461538462,48.036923076923074,51.51846153846154,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.74,12.336923076923076,14.933846153846154,17.53076923076923,20.127692307692307,22.724615384615383,25.32153846153846,27.918461538461536,30.515384615384612,33.11230769230769,35.709230769230764,38.30615384615384,40.903076923076924,{"y":43.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.74,11.144615384615385,12.54923076923077,13.953846153846154,15.358461538461537,16.763076923076923,18.167692307692306,19.57230769230769,20.976923076923075,22.38153846153846,23.786153846153844,25.190769230769227,26.59538461538461,{"y":28,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":61.18,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.84,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.79,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.52,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.34,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.74,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >